Novel predictors of neurosyphilis among HIV-negative syphilis patients with neurological symptoms: an observational study

Yao Xiao †, Man-Li Tong †, Li-Li Liu †, Li-Rong Lin, Mei-Jun Chen, Hui-Lin Zhang, Wei-Hong Zheng, Shu-Lian Li, Hui-Ling Lin, Zhi-Feng Lin, Hui-Qin Xing, Jian-Jun Niu, and Tian-Ci Yang

Abstract

Background: Known predictors of neurosyphilis were mainly drawn from human immunodeficiency virus (HIV)-infected syphilis patients, which may not be applicable to HIV-negative populations as they have different characteristics, particularly those with neurological symptoms. This study aimed to identify novel predictors of HIV-negative symptomatic neurosyphilis (S-NS).

Methods: From June 2005 to June 2015, 370 HIV-negative syphilis patients with neurological symptoms were recruited, consisting of 191 S-NS patients (including 123 confirmed neurosyphilis and 68 probable neurosyphilis patients) and 179 syphilis/non-neurosyphilis (N-NS) patients. Clinical and laboratory characteristics of S-NS were compared with N-NS to identify factors predictive of S-NS. Serum rapid plasma reagin (RPR), Treponema pallidum particle agglutination (TPPA), and their parallel testing format for screening S-NS were evaluated.

Results: The likelihood of S-NS was positively associated with the serum RPR and TPPA titers. The serum TPPA titers performed better than the serum RPR titers in screening S-NS. The optimal cut-off points to recognize S-NS were serum RPR titer ≥ 1:4 and serum TPPA titer ≥ 1:2560 respectively. A parallel testing format of a serum RPR titer ≥ 1:2 and serum TPPA titer ≥ 1:1280 screened out 95.8% of S-NS and all confirmed cases of neurosyphilis. S-NS was independently associated with male sex, serum RPR titer ≥ 1:4, serum TPPA titer ≥ 1:2560, and elevated serum creatine kinase. Concordance of these factors increased the likelihood of S-NS.

Conclusions: Quantitation of serum TPPA is worthwhile and performs better than serum RPR in screening S-NS. Serum RPR, serum TPPA, male sex, and serum creatine kinase can predict S-NS. Moreover, patients with both a serum RPR titer < 1:2 and a serum TPPA titer < 1:1280 have a low probability of S-NS, suggesting that it is reasonable to reduce lumbar punctures in such individuals.

Keywords: Symptomatic neurosyphilis, Predictors, Lumbar puncture, Rapid plasma reagin, Treponema pallidum particle agglutination
Background
Syphilis, caused by *Treponema pallidum*, remains the third prevalent notifiable infectious disease in China in the past decade ([http://www.stats.gov.cn/english/](http://www.stats.gov.cn/english/)). Neurosyphilis can develop at any time in the course of syphilis. The organism invades the central nervous system in the early course of disease and likely disseminates before the clinical manifestations of primary syphilis, which is called "neuroinvasion" [1]. Those who fail to clear the organisms are deemed to have "asymptomatic neurosyphilis" and are at risk for subsequent development of neurological symptoms. The clinical manifestations of symptomatic neurosyphilis (S-NS) are protean, exact replicas of the symptoms of various neurological disorders, and it is difficult to distinguish S-NS from other central nervous system diseases, which can significantly delay treatment. Conventionally, diagnosis of neurosyphilis is based on a reactive venereal disease research laboratory (VDRL) test, pleocytosis and/or elevated protein concentrations in cerebrospinal fluid (CSF) collected by lumbar puncture. Although lumbar puncture is invasive, syphilis patients would be considered for CSF assessment on the condition of clinical evidence of neurological, ocular or auricular involvement; tertiary syphilis; congenital syphilis; or failure to achieve an adequate response to treatment [2, 3]. Some experts even recommend CSF examination in all human immunodeficiency virus (HIV)-infected individuals with any stage of syphilis [3]. Researchers have sought to identify predictors for the early recognition of neurosyphilis to avoid unnecessary lumbar puncture. Recently, neurosyphilis was found to be more prevalent in HIV-infected individuals with high (≥1:32) serum rapid plasma reagin (RPR) titers or low (<350 cells/μL) peripheral blood CD4+ T cell counts, and lumbar puncture was recommended in such individuals [4]. However, HIV-negative individuals seemed to have lower serum VDRL and *T. pallidum* particle agglutination (TPPA) titers [5]; therefore, such a selective approach for lumbar puncture may not be applicable to the scenario where syphilis is prevalent among HIV-negative key populations, such as China [6]. A survey showed 13.6% of HIV-negative syphilis patients were diagnosed with S-NS [7].

To the best of our knowledge, previous studies have rarely concentrated on HIV-negative syphilis patients [8–10], particularly those with neurological symptoms. This study aimed to identify predictive factors of S-NS and to explore serological indicators for lumbar puncture in HIV-negative syphilis patients with neurological symptoms over a ten-year period.

Methods
Study population and ethics statement
This study was conducted at Zhongshan Hospital, Medical College of Xiamen University from June 2005 to June 2015. A total of 5,226 hospitalized patients were clinically diagnosed with syphilis by combining serodiagnosis and medical history. Patients were excluded from the study as follows: return visit, without lumbar puncture, without complete medical records, without neurological symptoms, HIV infection. At last, 370 HIV-negative syphilis patients with neurological symptoms were enrolled in this study (Fig. 1). Clinical information was extracted and recorded for each participant, including medical history, physical examination and laboratory investigation. This study was approved by the Institutional Ethics Committee of Zhongshan Hospital, Medical College of Xiamen University, and it was in compliance with national legislation and the Declaration of Helsinki guidelines. Written informed consent was obtained from all study participants.

Diagnostic criteria
The diagnostic criteria for neurosyphilis complied with the guidelines of the Centers for Disease Control in America and Europe [2, 11]. The neurosyphilis cases were subdivided into confirmed neurosyphilis and probable neurosyphilis. Confirmed neurosyphilis is defined as syphilis of any stage with reactive RPR in CSF. Probable neurosyphilis is defined as syphilis of any stage with a negative CSF-RPR test and both of the following: (1) elevated CSF protein (>500 mg/L) and/or leukocyte count (>10 cells/μL) in the absence of other known causes of these abnormalities and (2) clinical symptoms or signs consistent with neurosyphilis without other known causes for these clinical abnormalities. Syphilis/non-neurosyphilis (N-NS) was defined as syphilis of any stage excluding neurosyphilis.

![Fig. 1](http://example.com/fig1.png)
Laboratory tests
The syphilitic serological tests for each sample were performed using RPR (InTec, Xiamen, China) and TPPA (Fujirebio, Tokyo, Japan) tests according to the manufacturer's instructions and as previously reported [12]. Other biochemical parameters were also consistent with our previous studies [12-14], including CSF protein, albumin, lactate, lactate dehydrogenase, chloride, glucose, and leukocyte count, as well as blood HbA1c, fasting plasma glucose, creatine kinase (CK), homocysteine, triglyceride, total cholesterol, alanine transaminase, aspartate transaminase, total bilirubin, urea nitrogen and creatinine.

Statistical analysis
The Mann-Whitney U test was used for continuous variables with skewed distribution, and a χ² test or Fisher’s exact test was used for categorical variables. The logistic regression model was used to test the associations between different variables and the development of neurosyphilis. Spearman’s rank correlation was used to analyze the correlation between serum RPR and TPPA reactivity. The above-mentioned statistical analyses were performed using SPSS 19.0 for Windows (SPSS Inc., Chicago, Illinois, USA). Receiver operating characteristic (ROC) analysis was performed to determine the performance of serum RPR and TPPA titer in screening S-NS, and the optimal cut-off points were determined corresponding to the maximal Youden’s index (sensitivity+specificity=100%). Comparison of ROC curves was carried out using Medcalc version 12.3.0 (Broekstraat 52, 9030; Mariakerke, Belgium). A two-sided P-value of <0.05 was considered statistically significant.

Results
Characteristics of the study participants
Over a ten-year period, a total of 370 HIV-negative syphilis patients with neurological symptoms were included in this study, consisting of 191 S-NS and 179 N-NS patients (Fig. 1). One hundred and twenty-three of the 191 S-NS patients met the definition of confirmed neurosyphilis, and 68 were defined as probable neurosyphilis. Overall, 70.5% (261/370) of these participants were males, accounting for 78.0% in the S-NS group and 62.6% in the N-NS group (P=0.001). The median age of all study participants was 53 (range, 21-85). There was no significant difference in age distribution between S-NS and N-NS patients (P=0.661). The most common neurological symptom of S-NS patients was cognitive decline (31.4%), followed by hemiparesis or hemiplegia (17.3%), dysbasia (16.8%). Other less common symptoms (<15%) included: aphasia, seizure, headache, disturbance of consciousness, bowel and bladder dysfunction, vision loss, vomiting, vertigo, neck stiffness, numbness in the lower extremities. S-NS patients had significantly higher serum RPR titers (median, 1:16; interquartile range [IQR], 1:4-1:64) and serum TPPA titers (median, 1:10240; IQR, 1:2560-1:20480) than N-NS patients (P<0.001). CSF protein, albumin and lactate levels and CSF leukocyte counts were higher and CSF glucose lower in the S-NS group than in the N-NS group (P<0.05). There was no difference between S-NS and N-NS in intracranial pressure, CSF chloride and lactate dehydrogenase. Among the 191 S-NS patients, those with probable neurosyphilis had lower serum RPR titers (median, 1:2 versus 1:32, P<0.001) and serum TPPA titers (median, 1:2560 versus 1:20480, P<0.001) than patients with confirmed neurosyphilis. CSF RPR and TPPA titers, CSF leukocyte counts and protein levels were also lower, whereas CSF glucose and lactate dehydrogenase were higher in the probable neurosyphilis subgroup than in the confirmed neurosyphilis subgroup (P<0.05) (Table 1).

Screening performance of serum RPR and serum TPPA for S-NS
We compared the serological characteristics between S-NS and N-NS. As the serum RPR titer increased, the number of S-NS cases gradually increased (Fig. 2a). The association with S-NS increased significantly with the serum RPR titers (P for trend <0.001) (Table 2). Patients with higher serum RPR titers compared to patients with relatively lower serum RPR titers (e.g., serum RPR titer ≥1:2 versus serum RPR titer <1:2) were more likely to be diagnosed with S-NS. Similarly, as the serum TPPA titer increased, the number of S-NS cases increased, and a clustered peak of values can be observed to the right in Fig. 2b. The likelihood of S-NS was positively associated with the reactivity of serum TPPA (P for trend <0.001) (Table 2). Patients with higher serum TPPA titers compared to patients with relatively lower serum TPPA titers (e.g., serum TPPA titer ≥1:1280 versus serum TPPA titer <1:1280) were more likely to be diagnosed with S-NS.
TPPA titer still had a relatively better performance than serum RPR titer \( (P=0.003) \) (Fig. 3c). Furthermore, we also found a correlation between serum RPR and serum TPPA reactivity \( (r_s=0.775, P<0.001) \). The optimal cut-off points of serological tests for the identification of S-NS were serum RPR titer ≥1:4 and serum TPPA titer ≥1:2560 (Fig. 3a). A threshold of serum RPR titer ≥1:4 provided a sensitivity of 76.6%, specificity of 79.8% and negative predictive values (NPV) of 76.3% in screening S-NS. A threshold of serum TPPA titer ≥1:2560 provided a

### Table 1 Clinical characteristics of the study participants

|                | N-NS (n=179) | S-NS (n=191) | \( P^a \) | S-NS Confirmed (n=123) | S-NS Probable (n=68) | \( p^b \) | \( p^c \) | \( p^d \) |
|----------------|--------------|-------------|---------|------------------------|----------------------|---------|---------|---------|
| **Male**       | 112 (62.6%)  | 149 (78.0%) | 0.001   | 97 (78.9%)             | 52 (76.5%)           | 0.702   | 0.003   | 0.039   |
| **Age**        | 54 (45-64)   | 53 (46-61)  | 0.661   | 52 (46-60)             | 55 (45-64)           | 0.373   | 0.474   | 0.869   |
| Serum RPR titer| 1:1 (Negative-1:2) | 1:16 (1:4-1:64) | \( <0.001 <0.001 \) | 1:32 (1:16-1:64) | 1:2 (1:1-1:8) | \( <0.001 <0.001 <0.001 \) |
| Serum TPPA titer| 1:640 (1:320-1:1280) | 1:10240 (1:2560-1:20480) | \( <0.001 <0.001 \) | 1:20480 (1:1280-1:5120) | 1:2560 (1:1280-1:5120) | \( <0.001 <0.001 <0.001 \) |
| CSF RPR titer  | Negative     | 1:2 (Negative-1:4) | \( <0.001 <0.001 \) | 1:4 (1:2-1:8) | Negative | \( <0.001 <0.001 <0.001 \) |
| CSF TPPA titer | Negative     | 1:1280 (1:160-1:5120) | \( <0.001 <0.001 \) | 1:5120 (1:1280-1:10240) | 1:80 (1:80-1:640) | \( <0.001 <0.001 <0.001 \) |
| CSF leukocyte (cells/μL) | 4 (2-7) | 15 (6-48) | \( <0.001 <0.001 \) | 29 (12-59) | 6 (2-13) | \( <0.001 <0.001 <0.001 \) |
| CSF protein (mg/L) | 390.9 (289.9-540.0) | 606.0 (418.6-884.3) | \( <0.001 <0.001 \) | 733.9 (502.0-1025.0) | 443.1 (325.8-607.2) | \( <0.001 <0.001 <0.001 \) |
| CSF albumin (mg/L) | 249.0 (173.7-361.9) | 296.4 (220.0-456.2) | 0.003 | 296.4 (243.0-500.6) | 297.0 (182.7-446.2) | 0.218 | 0.001 | 0.183 |
| CSF glucose (mmol/L) | 3.70 (3.40-4.20) | 3.54 (3.21-4.19) | 0.037 | 3.48 (3.12-4.08) | 3.74 (3.25-4.20) | 0.030 | 0.003 | 0.913 |
| CSF chloride (mmol/L) | 124.3 (121.9-126.4) | 124.4 (121.5-126.3) | 0.696 | 124.8 (121.5-126.5) | 123.9 (121.6-125.9) | 0.303 | 0.902 | 0.330 |
| CSF lactate (mmol/L) | 1.76 (1.57-2.02) | 1.89 (1.67-2.17) | 0.043 | 1.90 (1.73-2.30) | 1.83 (1.66-2.06) | 0.160 | 0.018 | 0.516 |
| CSF lactate dehydrogenase (U/L) | 20.2 (16.7-27.7) | 20.2 (16.0-26.5) | 0.696 | 19.5 (16.0-23.6) | 22.2 (17.8-34.1) | 0.032 | 0.131 | 0.184 |
| Intracranial pressure (mmH2O) | 135 (110-160) | 140 (110-160) | 0.604 | 140 (110-160) | 140 (100-160) | 0.882 | 0.656 | 0.692 |

N-NS syphilis/non-neurosyphilis, S-NS symptomatic neurosyphilis, RPR rapid plasma reagin, TPPA *T. pallidum* particle agglutination, CSF cerebrospinal fluid, \( P^a \) Comparison between the S-NS group and the N-NS group, \( P^b \) Comparison between the confirmed neurosyphilis subgroup and the probable neurosyphilis subgroup, \( P^c \) Comparison between the confirmed neurosyphilis subgroup and the N-NS, \( P^d \) Comparison between the probable neurosyphilis subgroup and the N-NS.

*Data with skewed distribution was described using median (interquartile range)

---

TPPA titer still had a relatively better performance than serum RPR titer \( (P=0.003) \) (Fig. 3c). Furthermore, we also found a correlation between serum RPR and serum TPPA reactivity \( (r_s=0.775, P<0.001) \). The optimal cut-off points of serological tests for the identification of S-NS were

---

**Fig. 2** Serological reactions to syphilis among S-NS and N-NS patients: (a) Serum RPR reactivity; (b) Serum TPPA reactivity. Units on the Y axis described the number of participants whose results was in each bar.
higher sensitivity of 83.0% ($P=0.043$), a specificity of 82.6%, and a NPV of 82.1% in screening S-NS.

Parallel testing algorithm of serum RPR and serum TPPA for screening S-NS

We combined the serum RPR test with the serum TPPA test in a parallel testing format, which referred to either serum RPR titer $\geq 1:4$ or serum TPPA titer $\geq 1:2560$, or both. With this algorithm, a significantly higher sensitivity of 87.8% ($P<0.05$) was obtained for discovering S-NS. The NPV was also raised to 84.9% (Table 3). To our surprise, using this format, the sensitivity and NPV in screening confirmed neurosyphilis could be as high as 97.5% and 98.0%, respectively. To achieve better screening performance, we

Table 2 Serum RPR and serum TPPA reactivity associated with S-NS

| Serum RPR titters | S-NS | N-NS | OR | $P$ | Serum TPPA titters | S-NS | N-NS | OR | $P$ |
|-------------------|------|------|----|-----|-------------------|------|------|----|-----|
| Negative          | 6(3.2) | 68(38.2) | 1.0 | (Ref.) | | | |
| 1:1               | 17(9.0) | 38(21.3) | 5.070 | <0.001 | | | |
| 1:2               | 21(11.2) | 36(20.2) | 6.611 | <0.001 | | | |
| 1:4               | 18(9.6) | 13(7.3) | 15.692 | <0.001 | | | |
| 1:8               | 16(8.5) | 8(4.5) | 22.667 | <0.001 | | | |
| 1:16              | 24(12.8) | 5(2.8) | 54.400 | <0.001 | | | |
| 1:32              | 26(13.8) | 7(3.9) | 42.095 | <0.001 | | | |
| 1:64              | 35(18.6) | 10(6.0) | 396.667 | <0.001 | | | |
| $\geq 1:128$      | 25(13.3) | 2(1.1) | 141.667 | $P$ for trend <0.001 | | | |
| Serum TPPA titters | | | |
| $\leq 1:160$      | 2(1.1) | 42(22.5) | 1.0 | (Ref.) | | | |
| 1:320             | 5(2.7) | 41(23.0) | 2.439 | 0.303 | | | |
| 1:640             | 7(3.7) | 32(18.0) | 4.375 | 0.078 | | | |
| 1:1280            | 18(9.6) | 34(19.1) | 10.588 | 0.003 | | | |
| 1:2560            | 23(12.2) | 12(6.7) | 38.333 | <0.001 | | | |
| 1:5120            | 21(11.2) | 11(6.2) | 38.182 | <0.001 | | | |
| 1:10240           | 29(15.4) | 5(2.8) | 116.000 | <0.001 | | | |
| $\geq 1:20480$    | 83(44.1) | 3(1.7) | 553.333 | <0.001 | | | |

**Table 2** Serum RPR and serum TPPA reactivity associated with S-NS

- **S-NS**: symptomatic neurosyphilis, **N-NS**: syphilis/non-neurosyphilis, **RPR**: rapid plasma reagin, **TPPA**: T. pallidum particle agglutination, **OR**: odds ratio, **Ref.**: reference
- This group included two S-NS patients and 21 N-NS patients with serum TPPA titers of 1:160 and 19 N-NS patients with serum TPPA titers of 1:80
- $P$ for trend $<0.001$
- $P$ for trend $<0.001$

Fig. 3 Screening performance of serum RPR and serum TPPA reactivity: (a) for the identification of S-NS, (b) for the identification of confirmed neurosyphilis, (c) for the identification of probable neurosyphilis
set thresholds by combining serum RPR titers decreased from 1:4 to 1:2 with serum TPPA titers decreased from 1:2560 to 1:1280 (Table 3). A parallel testing format of serum RPR titer ≥1:2 and serum TPPA titer ≥1:1280 was found to be optimal, with a sensitivity of 95.8% and an NPV of 91.2% in screening neurosyphilis. Moreover, all of the confirmed neurosyphilis cases would be screened out at this threshold.

**Univariate and multivariate analyses of factors predictive of S-NS**

In the univariate analysis, previous psychiatric disorders, elevated CK and elevated homocysteine were more common in S-NS than in N-NS (P<0.05). Compared with N-NS, the proportion of previous ischemic stroke in probable neurosyphilis and the proportion of elevated fasting plasma glucose in confirmed neurosyphilis were higher (P<0.05). Notably, five S-NS patients with chronic alcoholism were all confirmed cases. There was no significant difference between S-NS and N-NS in other central nervous system infections, brain injury, brain tumors, previous hemorrhagic stroke, hypertension, heart diseases, diabetes mellitus, blood lipid, liver function or renal function (Table 4). Further multivariate analysis showed that S-NS was independently associated with male sex (odds ratio [OR], 2.376; 95% confidence interval [CI], 1.116 to 5.059), serum RPR titer ≥1:4 (OR, 3.610; 95% CI, 1.674 to 7.783), serum TPPA titer ≥1:2560 (OR, 7.290; 95% CI, 3.384 to 15.707), and elevated serum CK (OR, 4.335; 95% CI, 1.213 to 15.493). Separate analysis of confirmed and probable neurosyphilis yielded similar results (data not shown).

**Combined effects of the independent risk factors of S-NS**

We further analyzed the combined effects of the independent risk factors mentioned above for S-NS (Table 5). Among female syphilis patients, patients with both serum RPR titer ≥1:4, TPPA titer ≥1:2560, and normal serum CK were in greater danger than those with serum RPR titer <1:4, serum TPPA titer <1:2560 and normal serum CK, with an OR of 20.583 (95% CI, 5.853 to 72.380) for S-NS and an OR of 104.000 (95% CI, 11.575 to 934.402) for confirmed neurosyphilis. Male patients were at higher risk than female patients. Compared with female patients with serum RPR titer <1:4, serum TPPA titer <1:2560 and normal serum CK, male patients with serum RPR titer ≥1:4, serum TPPA titer ≥1:2560, and normal serum CK had a markedly increased likelihood of S-NS (OR, 53.300; 95% CI, 18.073 to 157.194), as well as confirmed neurosyphilis (OR, 265.200; 95% CI, 32.704 to 2150.534) and probable neurosyphilis (OR, 10.920; 95% CI, 3.176 to 37.549). Notably, in both male and female patients, there were 22 patients with concurrent serum RPR titer ≥1:4, serum TPPA titer ≥1:2560 and elevated CK who all had neurosyphilis (data not shown).

**Discussion**

Whether and when to conduct the CSF examination in syphilis patients continues to plague clinicians. Some risk factors of neurosyphilis have been reported in HIV-infected individuals, including male sex, higher serum RPR titers and the occurrence of neurological symptoms, as well as profiles of HIV infection (e.g., higher HIV viral load and lower peripheral blood CD4+ T cells) [4, 8, 10]. However, HIV-negative syphilis patients had different characteristics from HIV-infected patients [5], and predictors of neurosyphilis in HIV-negative patients have rarely been discussed, especially in S-NS. To the best of our knowledge, this is the first report to discuss this issue, and it includes a large amount of information as well as a great number of subjects. Except for male sex and increased serum RPR titers, we also found that increased serum TPPA titers and elevated serum CK can be predictors of S-NS. Moreover, patients with both serum RPR titer <1:2 and serum TPPA titer <1:1280 were unlikely to have S-NS. Considering the invasiveness of lumbar puncture, the identification of predictors of neurosyphilis to avoid unnecessary lumbar puncture has been a hotspot in clinical research. In the present study, as the serum RPR titers gradually increased, we observed a rising trend in the likelihood of S-NS in HIV-negative patients, which coincided with a previous study of HIV-infected neurosyphilis patients [15]. In syphilis patients co-infected with HIV, serum RPR titers of 1:32 or 1:16 were recommended as indicators to determine the need for lumbar punctures in patients without neurological symptoms [9, 15]. However, among our HIV-negative subjects with neurological

---

**Table 3** Screening performance of parallel testing of serum RPR and serum TPPA for S-NS

| Parallel testing format | Identification of S-NS | Identification of confirmed neurosyphilis | Identification of probable neurosyphilis |
|-------------------------|------------------------|------------------------------------------|----------------------------------------|
|                         | Sensitivity (%)         | Specificity (%)                          | NPV (%)                                |
| RPR≥1:4, TPPA≥1:2560*   | 87.8                   | 72.5                                     | 84.9                                   |
| RPR≥1:2, TPPA≥1:2560    | 92.6                   | 55.6                                     | 87.6                                   |
| RPR≥1:4, TPPA≥1:1280    | 93.1                   | 58.7                                     | 89.0                                   |
| RPR≥1:2, TPPA≥1:1280    | 95.8                   | 46.4                                     | 91.2                                   |

* A positive screening result was defined as either serum RPR titer ≥1:4 or serum TPPA titer ≥1:2560, or both. And by this analogy

**S-NS** symptomatic neurosyphilis, **N-NS** syphilis/non-neurosyphilis, **RPR** rapid plasma reagin, **TPPA** T. pallidum particle agglutination, **PPV** positive predictive value, **NPV** negative predictive value.
Table 4 Comparison between S-NS and N-NS in comorbidities and serum biochemical parameters

| Comorbidities                  | S-NS (n=191) n (%) | N-NS (n=179) n (%) | p*   | S-NS confirmed (n=123) n (%) | Probable (n=68) n (%) | p*   | p*   |
|--------------------------------|--------------------|--------------------|------|-----------------------------|-----------------------|------|------|
| Comorbidities                  |                    |                    |      |                             |                       |      |      |
| Other CNS infectionsd          | 3 (1.6)            | 0                  | 0.249| 3 (2.4)                     | 0                     | 0.067| n.a. |
| Brain injury                   | 7 (3.7)            | 5 (2.8)            | 0.636| 6 (4.9)                     | 1 (1.5)               | 0.364| 1.0  |
| Brain tumors                   | 2 (1.0)            | 3 (1.7)            | 0.676| 1 (0.8)                     | 1 (1.5)               | 0.648| 1.0  |
| Psychiatric disorders          | 12 (6.3)           | 2 (1.1)            | 0.009| 7 (5.7)                     | 5 (7.4)               | 0.034| 0.018|
| History of ischemic stroke     | 36 (18.8)          | 24 (13.4)          | 0.156| 19 (15.4)                   | 17 (25.0)             | 0.618| 0.029|
| History of hemorrhagic stroke  | 0                  | 4 (2.2)            | 0.054| 0                           | 0                     | 0.148| 0.578|
| Hypertension                   | 83 (43.5)          | 85 (47.5)          | 0.436| 47 (38.2)                   | 36 (52.9)             | 0.110| 0.444|
| Heart diseases e                | 32 (16.8)          | 33 (18.4)          | 0.671| 19 (15.4)                   | 13 (19.1)             | 0.499| 0.902|
| Diabetes mellitus              | 59 (30.9)          | 40 (22.3)          | 0.064| 37 (30.1)                   | 22 (32.4)             | 0.130| 0.105|
| Chronic alcoholism             | 5 (2.6)            | 1 (0.6)            | 0.216| 5 (4.1)                     | 0                     | 0.043| 1.0  |
| Serum biochemical parameters   |                    |                    |      |                             |                       |      |      |
| Elevated FPG (≥7.0 mmol/L)     | 38 (19.9)          | 24 (13.4)          | 0.095| 30 (24.4)                   | 8 (11.8)              | 0.014| 0.731|
| Elevated HbA1c (≥6.5%)         | 36 (28.3)          | 29 (25.4)          | 0.612| 22 (27.2)                   | 14 (30.4)             | 0.787| 0.519|
| Elevated CK (male ≥308, female ≥192 U/L) | 30 (16.9) | 19 (17.0) | 0.003 | 11 (16.9) |                       | 0.006| 0.117|
| Elevated HCY9                  | 42 (32.1)          | 22 (18.3)          | 0.013| 25 (32.9)                   | 17 (30.9)             | 0.020| 0.063|
| Elevated TG (≥1.70 mmol/L)     | 41 (22.3)          | 41 (24.6)          | 0.616| 22 (18.6)                   | 19 (28.8)             | 0.237| 0.505|
| Elevated CHOL (≥2.22 mmol/L)   | 8 (4.3)            | 11 (6.6)           | 0.355| 3 (2.5)                     | 5 (7.6)               | 0.120| 0.778|
| Elevated ALT (male ≥50, female ≥40 U/L) | 14 (7.3) | 16 (9.0) | 0.560 | 11 (8.9) | 3 (4.4)               | 0.989| 0.229|
| Elevated AST (male ≥40, female ≥35 U/L) | 21 (11.1) | 15 (8.5) | 0.407 | 16 (13.0) | 5 (7.5)               | 0.205| 0.797|
| Elevated TBIL (≥17.1 μmol/L)   | 34 (18.1)          | 26 (15.0)          | 0.436| 23 (18.9)                   | 11 (16.7)             | 0.385| 0.754|
| Elevated BUN (≥28.2 mmol/L)    | 8 (4.2)            | 12 (6.7)           | 0.285| 6 (4.9)                     | 2 (2.9)               | 0.510| 0.361|
| Elevated sCr (male ≥115, female ≥97 μmol/L) | 6 (3.1) | 12 (6.7) | 0.111 | 2 (1.6) | 4 (5.9)               | 0.039| 1.0  |

S-NS symptomatic neurosyphilis, N-NS syphilis/non-neurosyphilis, CNS central nervous system, FPG fasting plasma glucose, HbA1c glycated hemoglobin (A1c), CK creatine kinase, HCY homocysteine, TG triglyceride, CHOL cholesterol, ALT alanine transaminase, AST aspartate transaminase, TBIL total bilirubin, BUN blood urea nitrogen, sCr serum creatinine

*p* Comparison between the S-NS group and the N-NS group, *p* Comparison between the confirmed neurosyphilis subgroup and the N-NS group, *p* Comparison between the probable neurosyphilis subgroup and the N-NS group

dTwo patients had viral encephalitis and one patient had viral meningitis before being diagnosed with S-NS

eHeart diseases includes coronary heart disease, hypertensive heart disease, valvular heart disease and cardiac arrhythmia

fOne patient with acute myocardial infarction was excluded

gHomocysteine ≥15 μmol/L in male or ≥12 μmol/L in female in <60 age group, or ≥20 μmol/L in ≥60 age group

symptoms, a titer of 1:4 was found to be the optimal cut-off point to recognize S-NS, with a sensitivity of 76.6%. If serum RPR titer ≥1:32 or titer ≥1:16 was used to screen for S-NS, 102 (54.3%) or 78 (41.5%) cases of S-NS would be missed, respectively. Of course, if serum RPR titer ≥1:4 was used as an indicator for lumbar puncture, there were still 44 (23.4%) cases that would be missed (including seven confirmed and 37 probable neurosyphilis cases). Therefore, new indicators are urgently needed.

Conventionally, treponemal tests are considered to be irrelevant to disease activity [2]; therefore, there is little research linking the treponemal antibody with neurosyphilis. Interestingly, we found a correlation between serum RPR and serum TPPA reactivity. Furthermore, compared with serum RPR titers, serum TPPA titers even had better screening performance, with an AUC of 0.897 for identification of S-NS. Of course, the sole use of serum RPR or TPPA titer might not adequately predict S-NS in HIV-negative patients. Therefore, we conducted a parallel testing format (either serum RPR titer ≥1:4 or serum TPPA titer ≥1:2560, or both) and found that it had a higher sensitivity (87.8%) in screening S-NS than using only serum RPR or TPPA alone. To achieve a higher sensitivity, we found that the parallel testing format of serum RPR ≥1:2
Table 5 Odds ratios of S-NS (with 95% confidence intervals) according to gender, syphilitic serological characteristics and serum creatine kinase levels

|                | Serum RPR titer <1:4 | Serum RPR titer ≥1:4 |
|----------------|----------------------|----------------------|
|                | Serum TPPA titer <1:2560 | Serum TPPA titer ≥1:2560 |
|                | Normal CK | Elevated CK | Normal CK | Elevated CK | Normal CK | Elevated CK | Normal CK | Elevated CK |
| S-NS           |           |            |           |            |           |            |           |            |
| Female         | 1.0 (Ref) | n.a.      | 6.500* (1.273-33.201) | n.a.      | 2.437 (0.502-11.845) | n.a.      | 20.583* (5.853-72.380) | n.a.      |            |
| Male           | 1.264 (0.395-3.550) | 3.900 (0.734-20.709) | 9.286* (2.549-33.832) | 9.750* (1.340-70.966) | 4.643* (1.107-19.475) | 6.500 (0.357-118.370) | 53.300* (18.073-157.194) | n.a.      |            |
| Confirmed neurosyphilis |           |            |           |            |           |            |           |            |
| Female         | 1.0 (Ref) | n.a.      | 9.750 (0.507-187.526) | n.a.      | 4.875 (0.275-86.351) | n.a.      | 104.000* (11.575-934.402) | n.a.      |            |
| Male           | 1.083 (0.095-12.329) | n.a.   | 39.000* (2.397-634.654) | n.a.      | 11.143 (0.886-140.119) | n.a.      | 265.200* (32.704-2150.534) | n.a.      |            |
| Probable neurosyphilis |           |            |           |            |           |            |           |            |
| Female         | 1.0 (Ref) | n.a.      | 5.850* (1.004-34.100) | n.a.      | 1.950 (0.320-11.888) | n.a.      | 3.900 (0.734-20.709) | n.a.      |            |
| Male           | 1.300 (0.427-3.959) | 4.680 (0.849-25.811) | 11.143* (2.913-42.620) | 3.900 (0.297-31.196) | 3.343 (0.647-17.267) | 7.800 (0.419-145.200) | 10.920* (3.176-37.549) | n.a.      |            |

S-NS symptomatic neurosyphilis, N-NS syphilis/non-neurosyphilis, RPR rapid plasma reagin, TPPA T. pallidum particle agglutination, CK creatine kinase, OR odds ratio, Ref. reference, n.a. not applicable
*P<0.05

aNo female patient with serum RPR titer <1:4, TPPA titer <1:2560 and elevated CK was in the S-NS group; the OR of S-NS was not applicable
bNo female patient with serum RPR titer <1:4, TPPA titer ≥1:2560 and elevated CK was in the N-NS group; the OR of S-NS was not applicable
cNo female patient with serum RPR titer ≥1:4, TPPA titer <1:2560 and elevated CK was in the N-NS group; the OR of S-NS was not applicable
dIn both male and female patients, there was no one with serum RPR titer ≥1:4, TPPA titer ≥1:2560 and elevated CK in the N-NS group; the OR of S-NS was not applicable
eNo male patient with serum RPR titer <1:4, TPPA titer <1:2560 and elevated CK was in both groups; the OR of S-NS was not applicable

and serum TPPA ≥1:1280 could screen out 95.8% of S-NS and even all confirmed neurosyphilis cases. Therefore, there is a low-probability of a missed diagnosis of S-NS in patients with both serum RPR titer <1:2 and serum TPPA titer <1:1280. The threshold also provided an NPV of 91.2%, i.e., 91.2% of patients excluded from the screening test could be correctly identified as N-NS. This parallel testing algorithm based on serological results may provide a preliminary judgment of S-NS for clinicians, especially in under-resourced settings where the lumbar puncture could not be performed in time, as well as allow for the rational use of medical resources.

The multivariate analyses showed that male sex, serum RPR titer ≥1:4, serum TPPA titer ≥1:2560, and elevated serum CK were independently associated with S-NS. Upon further analysis, the effects of these variables on the risk of developing S-NS appeared to be synergistic. Having both serum RPR titer ≥1:4 and TPPA titer ≥1:2560 increased the likelihood of S-NS with an odds ratio of 20.583 for female patients and up to 53.300 for male patients. The ORs of confirmed neurosyphilis in such patients were dramatically increased to 104.000 for female patients and up to 265.200 for male patients. As previously reported, male patients were more likely to develop neurosyphilis [6, 8]. Notably, those with serum RPR titer ≥1:4, TPPA titer ≥1:2560 and elevated serum CK were only observed in S-NS patients.

Previous studies on neurosyphilis were confined to demographic characteristics, stage of syphilis, serum RPR titer and profiles of HIV infection [4, 6, 9]. In this study, we took the comorbidities and biochemical parameters into consideration and found that serum CK could aid in the recognition of both confirmed and probable neurosyphilis. In humans, CK is found to be most concentrated and active in skeletal muscle and is released into circulation when these tissues are damaged [16]. Neurosyphilis can result in various movement disorders [17], which indicate involvement of the musculoskeletal system. In the present study, S-NS patients presented with hemiparesis or hemiplegia, dysbasia, seizure and numbness.

Our study benefited from a great number of neurosyphilis cases and variables. However, the present study is hospital-based, and only 10.4% (432/4152) of syphilis patients received lumbar puncture. Additionally, the epidemic of neurosyphilis among syphilis patients without CSF assessment was unknown. In addition, the RPR test was recommended in the CSF assessment in our country or in Europe, but the VDRL test was routinely used in the CSF assessment in previous studies, especially in the
United States. Therefore, our findings may not be similar to those studies using the VDRL test. Identifying predictors of asymptomatic neurosyphilis requires further research.

## Conclusion

To effectively identify neurosyphilis cases and perform practical lumbar punctures among HIV-negative syphilis patients are real challenges, especially in neurologically symptomatic patients. Our study found that the quantitation of serum TPPA is worthwhile, and it even performs better than serum RPR in screening S-NS. Serum RPR titer ≥1:4 and serum TPPA titer ≥1:2560 were the optimal cut-off points to distinguish S-NS from N-NS. Serum RPR and serum TPPA characteristics, male sex, and serum CK can be used as auxiliary indicators of S-NS. Notably, patients with both serum RPR titer <1:2 and serum TPPA titer <1:1280 had a low probability of neurosyphilis, suggesting that it is reasonable to reduce lumbar puncture in such individuals.

## Abbreviations

AUDC: Area under the ROC curve; CK: Creatine kinase; CSF: Cerebrospinal fluid; HIV: Human immunodeficiency virus; N-NS: Syphilis/non-neurosyphilis; ROC: Receiver operating characteristic; RPR: Rapid plasma reagent; S-NS: Symptomatic neurosyphilis; TPPA: Treponema pallidum particle agglutination; VDRL: Venereal disease research laboratory

## Acknowledgements

We acknowledge all the colleagues in the clinical laboratory, Zhongshan Hospital, Medical College of Xiamen University, for their assistance with sample collection, as well as their support in this project.

## Funding

This work was supported by the National Natural Science Foundation of China [grant numbers 8127335, 81201360, 81471967, 81471231, 81401749, 81301501, 81271895], the Key Projects in Fujian Province Science and Technology Program [grant numbers 20130025, 2014D021], the Projects of Xiamen Science and Technology Program [grant numbers 3502Z20144022, 3502Z20154015, W52010–01], the Key Project of Cultivating Young Talent in Fujian Province’s Health System [grant number 2014-ZQN-ZD-34], the National Science Foundation for Distinguished Young Scholars of Fujian [grant number 2014D001], the Youth Foundation Project of Fujian Provincial Health Department [grant numbers 2014-2-68, 2013-2-90], the medical innovation Project of Fujian Health Development Planning Commission [grant number 2014-CX-B40], the major special projects of serious illness in Xiamen [grant number 3502Z201559016], the Natural Science Foundation of Fujian Province [grant number 2016J01628, 2013J01358], and the 863 Program [grant numbers 2014AA021401, 2014AA02230]. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

## Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

## Authors’ contributions

JJN and TCY conceived and designed the study. MJJC, WHZ, SLL, HLH, and ZFL collected and organized the data. YX, MLT and LLL analyzed the data and drafted the manuscript. JJIN, TCY, LRL, HLZ, and HQX obtained the funding and revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

## Competing interests

The authors declare that they have no competing interests.

## Consent for publication

Not applicable.

## Ethics approval and consent to participate

This study was approved by the Institutional Ethics Committee of Zhongshan Hospital, Medical College of Xiamen University, and it was in compliance with national legislation and the Declaration of Helsinki guidelines. Written informed consent was obtained from all study participants.

## Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Author details

1. Zhongshan Hospital, Medical College of Xiamen University, Xiamen 361004, China. 2. Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361009, China. 3. Xiamen Zhongshan Hospital, Fujian Medical University, Xiamen 361004, China. 4. Xiamen Huili District Maternity and Child Care Hospital, Xiamen 361009, China. 5. Institute of Neuroscience, Medical College of Xiamen University, Xiamen 361005, China.

Received: 20 January 2017 Accepted: 24 March 2017

## References

1. Lukehart SA, Hook EW, Baker-Zander SA, Collier AC, Critchlow CW, Handsfield HH. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med. 1998;129:595–62.
2. Janser M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potocnik M, et al. 2014 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol. 2014;28:1581–93.
3. Wong T, Fonseca K, Chernsky MA, Garceau R, Levent PN, Serhir B. Canadian Public Health Laboratory Network laboratory guidelines for the diagnosis of neurosyphilis in Canada. Can J Infect Dis Med Microbiol. 2015;26:184–224.
4. Marra CM, Maxwell CL, Smith SL, Lukehart SA, Rompalo AM, Eaton M, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis. 2004;189:369–76.
5. Knaute DF, Graf N, Lautenschläger S, Weber R, Bossard PP. Serological response to treatment of syphilis according to disease stage and HIV status. Clin Infect Dis. 2012;55:1615–22.
6. Shi M, Peng RR, Gao Z, Zhang S, Lu H, Guan Z, et al. Risk profiles of neurosyphilis in HIV-negative patients with primary, secondary and latent syphilis: implications for clinical intervention. J Eur Acad Dermatol Venereol. 2016;30:659–66.
7. Zhu L, Gu X, Peng RR, Wang C, Gao Z, Zhou P, et al. Comparison of the cerebrospinal fluid (CSF) toluidine red unheated serum test and the CSF rapid plasma reagent test with the CSF venereal disease research laboratory test for diagnosis of neurosyphilis among HIV-negative syphilis patients in China. J Clin Microbiol. 2014;52:736–40.
8. Ghannem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS. 2008;22:1145–51.
9. Sun JJ, Wang ZY, Shen JY, Shen YZ, Liu L, Wang JR, et al. Serum TRUST Titer ≥1:16 Is a Predictor for Neurosyphilis Among HIV-Infected Patients With Concurrent Syphilis and No Neurological Symptoms. Medicine (Baltimore). 2015;94:e2023.
10. Dumaresq J, Langevin S, Gagnon S, Serhir B, Deligne B, Tremblay C, et al. Clinical prediction and diagnosis of neurosyphilis in HIV-infected patients with early Syphilis. J Clin Microbiol. 2013;51:4060–6.
11. Centers for Disease Control and Prevention. STD Surveillance Case Definitions. http://www.cdc.gov/std/stats/CaseDefinitions-2014.pdf. Accessed 1 Jan 2014.
12. Liu LL, Zhang HL, Huang SJ, Liu L, Tong ML, Lin LR, et al. Assessing cerebrospinal fluid abnormalities in neurosyphilis patients without human immunodeficiency virus infection. Int Immunopharmacol. 2013;17:1120–4.
13. Yang TC, Tong ML, Xi Y, Guo XJ, Chen YY, Zhang YF, et al. Association between neurosyphilis and diabetes mellitus: resurgence of an old problem. J Diabetes. 2014;6:403–8.

14. Xiao Y, Li SL, Lin HL, Lin ZF, Zhu XZ, Fan JY, et al. Factors associated with syphilis infection: a comprehensive analysis based on a case-control study. Epidemiol Infect. 2016;144:1165–74.

15. Libois A, De Wit S, Poll B, Garcia F, Florence E, Del Rio A, et al. HIV and syphilis: when to perform a lumbar puncture. Sex Transm Dis. 2007;34:141–4.

16. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80:1107–213.

17. Tong ML, Lin LR, Zhang HL, Huang SJ, Liu GL, Zheng WH, et al. Spectrum and characterization of movement disorders secondary to neurosyphilis. Parkinsonism Relat Disord. 2013;19:441–5.